November 4, 2013 — According to a study of diabetic patients who underwent revascularization for multivessel coronary artery disease (CAD), patients treated with insulin experienced more major adverse cardiovascular events after revascularization than those not treated with insulin. The findings of a sub group analysis of the FREEDOM trial were presented today at the 25th annual Transcatheter Cardiovascular Therapeutics scientific symposium (TCT 2013).
Results of the overall FREEDOM trial, which were first reported last year in the New England Journal of Medicine, found that coronary artery bypass grafting (CABG) reduces mortality and myocardial infarction rates compared to percutaneous coronary intervention (PCI), though it increases the chance of stroke. This FREEDOM sub group analysis examined the association of clinical outcomes after revascularization by insulin-treated diabetes mellitus (ITDM) status and the respective effect of CABG versus PCI using first generation drug-eluting stents (PCI/DES). The primary endpoint was a composite of major adverse cardiac events including death, stroke and myocardial infarction analyzed using the logrank test and Cox regression to assess the interaction of treatment received and ITDM status.
A total of 1,850 diabetic patients with multi-vessel disease were randomized one-to-one to either CABG (894 patients) or PCI/DES (956 patients). Baseline and procedure characteristics were largely similar among the groups. A total of 602 patients (32.5 percent) had ITDM (PCI n = 325, 34 percent; CABG n = 277, 31 percent).
The estimated percentage of patients with a major adverse coronary event after five years was higher in the ITDM group compared to the non ITDM group (29 percent versus 19 percent, respectively). Regardless of insulin treatment status, the estimated percentage of patients with major adverse coronary events after five years was higher among those who underwent PCI/DES (32 percent in the ITDM group and 25 percent in the non-ITDM group) compared to CABG (24 percent in the ITDM group and 16 percent in the non-ITDM group), although stroke rates were higher among CABG patients. In the ITDM group, the stroke rate was 7.5 for those who underwent CABG compared to 3.7 in those who had PCI/DES. In the non-ITDM group, the stroke rate was 4.3 versus 1.7 respectively.
“In patients with diabetes and multi-vessel coronary artery disease, there are more major adverse cardiovascular events in patients treated with insulin than in those not treated with insulin,” said George Dangas, M.D, Ph.D., professor of medicine, Mount Sinai School of Medicine, director of cardiovascular innovation, Zena and Michael A. Wiener Cardiovascular Institute of the Mount Sinai Medical Center and study investigator. “However, the differences in clinical outcomes between CABG and PCI/DES were maintained regardless of the presence or absence of insulin treatment.”
For more information: www.crf.org, www.nejm.org